Anna Höll

Anna Höll

Auto-generated profile, based on publicly available information

Anna Höll

Institute of Pharmaceutical Sciences, Pharmaceutical Chemistry, University of Graz, Graz, Austria

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
JKJohanna M. Kohlmayr
Johanna M. Kohlmayr
GGGernot F. Grabner
Gernot F. Grabner
ANAnna Nusser
Anna Nusser
AHAnna Höll
Anna Höll
VMVerina Manojlović
Verina Manojlović
USUlrich Stelzl
Ulrich Stelzl
ATGL is a key enzyme in intracellular lipolysis and plays an important role in metabolic and cardiovascular diseases. ATGL is tightly regulated by a known set of protein-protein interaction partners with activating or inhibiting functions in the control of lipolysis. Here, we use deep mutational protein interaction perturbation scanning and generate comprehensive profiles of single amino acid variants that affect the interactions of ATGL with its regulatory partners: CGI-58, G0S2, PLIN1, PLIN5 and CIDEC. Twenty-three ATGL amino acid variants yield a specific interaction perturbation pattern when validated in co-immunoprecipitation experiments in mammalian cells. We identify and characterize eleven highly selective ATGL switch mutations which affect the interaction of one of the five partners without affecting the others. Switch mutations thus provide distinct interaction determinants for ATGL’s key regulatory proteins at an amino acid resolution. When we test triglyceride hydrolase activity in vitro and lipolysis in cells, the activity patterns of the ATGL switch variants trace to their protein interaction profile. In the context of structural data, the integration of variant binding and activity profiles provides insights into the regulation of lipolysis and the impact of mutations in human disease.